3 Stocks Raising The Health Care Sector Higher

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Two out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading up 26 points (0.2%) at 15,572 as of Tuesday, July 23, 2013, 12:50 PM ET. The NYSE advances/declines ratio sits at 1,636 issues advancing vs. 1,285 declining with 117 unchanged.

The Health Care sector currently is unchanged today versus the S&P 500, which is down 0.1%. On the negative front, top decliners within the sector include Waters Corporation ( WAT), down 5.9%, Boston Scientific ( BSX), down 2.4%, Alexion Pharmaceuticals ( ALXN), down 2.0%, Vertex Pharmaceuticals ( VRTX), down 1.0% and Sanofi ( SNY), down 0.6%.

TheStreet would like to highlight 3 stocks pushing the sector higher today:

3. Novo Nordisk A/S ( NVO) is one of the companies pushing the Health Care sector higher today. As of noon trading, Novo Nordisk A/S is up $1.92 (1.2%) to $165.17 on average volume. Thus far, 167,761 shares of Novo Nordisk A/S exchanged hands as compared to its average daily volume of 305,100 shares. The stock has ranged in price between $163.67-$165.17 after having opened the day at $164.29 as compared to the previous trading day's close of $163.25.

Novo Nordisk A/S engages in the discovery, development, manufacture, and marketing of pharmaceutical products primarily in Denmark. It operates in two segments, Diabetes Care and Biopharmaceuticals. Novo Nordisk A/S has a market cap of $89.9 billion and is part of the drugs industry. Shares are up 0.1% year to date as of the close of trading on Monday. Currently there is 1 analyst that rates Novo Nordisk A/S a buy, 1 analyst rates it a sell, and 2 rate it a hold.

TheStreet Ratings rates Novo Nordisk A/S as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, impressive record of earnings per share growth, notable return on equity, expanding profit margins and compelling growth in net income. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Novo Nordisk A/S Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

2. As of noon trading, Hologic ( HOLX) is up $0.74 (3.3%) to $22.90 on heavy volume. Thus far, 4.7 million shares of Hologic exchanged hands as compared to its average daily volume of 3.5 million shares. The stock has ranged in price between $22.18-$23.04 after having opened the day at $22.27 as compared to the previous trading day's close of $22.17.

Hologic, Inc. develops, manufactures, and supplies diagnostics, medical imaging systems, and surgical products for women. Hologic has a market cap of $5.8 billion and is part of the health services industry. Shares are up 8.3% year to date as of the close of trading on Monday. Currently there are 12 analysts that rate Hologic a buy, 1 analyst rates it a sell, and 4 rate it a hold.

TheStreet Ratings rates Hologic as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, expanding profit margins and increase in stock price during the past year. However, as a counter to these strengths, we also find weaknesses including disappointing return on equity, weak operating cash flow and deteriorating net income. Get the full Hologic Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

1. As of noon trading, Teva Pharmaceutical Industries ( TEVA) is up $0.72 (1.8%) to $41.31 on heavy volume. Thus far, 3.5 million shares of Teva Pharmaceutical Industries exchanged hands as compared to its average daily volume of 3.5 million shares. The stock has ranged in price between $40.57-$41.65 after having opened the day at $40.70 as compared to the previous trading day's close of $40.59.

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes pharmaceutical products worldwide. Teva Pharmaceutical Industries has a market cap of $34.2 billion and is part of the drugs industry. Shares are up 7.4% year to date as of the close of trading on Monday. Currently there are 9 analysts that rate Teva Pharmaceutical Industries a buy, no analysts rate it a sell, and 13 rate it a hold.

TheStreet Ratings rates Teva Pharmaceutical Industries as a hold. The company's strengths can be seen in multiple areas, such as its attractive valuation levels, good cash flow from operations and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and a generally disappointing performance in the stock itself. Get the full Teva Pharmaceutical Industries Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

null

More from Markets

Dow and Nasdaq Finish Lower as 10-Year Treasury Yield Hovers Near 3%

Dow and Nasdaq Finish Lower as 10-Year Treasury Yield Hovers Near 3%

Video: Stop Using Student Loan Money to Buy Bitcoin

Video: Stop Using Student Loan Money to Buy Bitcoin

Let the Najarian Brothers Crash-Proof Portfolio

Let the Najarian Brothers Crash-Proof Portfolio

Facebook Sends Facial Recognition Notification in Error

Facebook Sends Facial Recognition Notification in Error

3 Hot Reads From TheStreet's Top Premium Columnists

3 Hot Reads From TheStreet's Top Premium Columnists